These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25256065)

  • 21. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate.
    Fukasawa LO; Gorla MC; Schenkman RP; Garcia LR; Carneiro SM; Raw I; Tanizaki MM
    Vaccine; 1999 Aug; 17(23-24):2951-8. PubMed ID: 10462229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
    Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
    Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with recombinant truncated Neisseria meningitidis-Macrophage Infectivity Potentiator (rT-Nm-MIP) protein induces murine antibodies that are cross-reactive and bactericidal for Neisseria gonorrhoeae.
    Humbert MV; Christodoulides M
    Vaccine; 2018 Jun; 36(27):3926-3936. PubMed ID: 29803329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.
    Micoli F; Romano MR; Tontini M; Cappelletti E; Gavini M; Proietti D; Rondini S; Swennen E; Santini L; Filippini S; Balocchi C; Adamo R; Pluschke G; Norheim G; Pollard A; Saul A; Rappuoli R; MacLennan CA; Berti F; Costantino P
    Proc Natl Acad Sci U S A; 2013 Nov; 110(47):19077-82. PubMed ID: 24191022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines.
    Baraldo K; Mori E; Bartoloni A; Petracca R; Giannozzi A; Norelli F; Rappuoli R; Grandi G; Del Giudice G
    Infect Immun; 2004 Aug; 72(8):4884-7. PubMed ID: 15271954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
    Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purified capsular polysaccharide of Neisseria meningitidis serogroup A as immune potentiator for antibody production.
    Menéndez T; Carmenate T; Cruz-Leal Y; Coizeau E; Caballero E; Bello D; Guirola M; Alvarez A; Guillén G
    Curr Microbiol; 2010 Feb; 60(2):79-84. PubMed ID: 19771476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bordetella pertussis fimbriae are effective carrier proteins in Neisseria meningitidis serogroup C conjugate vaccines.
    Reddin KM; Crowley-Luke A; Clark SO; Vincent PJ; Gorringe AR; Hudson MJ; Robinson A
    FEMS Immunol Med Microbiol; 2001 Aug; 31(2):153-62. PubMed ID: 11549423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
    Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
    Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.
    Blanchard Rohner G; Snape MD; Kelly DF; John T; Morant A; Yu LM; Borkowski A; Ceddia F; Borrow R; Siegrist CA; Pollard AJ
    J Immunol; 2008 Feb; 180(4):2165-73. PubMed ID: 18250423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical studies on new proteins as carrier for glycoconjugate vaccines.
    Tontini M; Romano MR; Proietti D; Balducci E; Micoli F; Balocchi C; Santini L; Masignani V; Berti F; Costantino P
    Vaccine; 2016 Jul; 34(35):4235-4242. PubMed ID: 27317455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
    Khatami A; Snape MD; Davis E; Layton H; John T; Yu LM; Dull PM; Gill CJ; Odrjlin T; Dobson S; Halperin SA; Langley JM; McNeil SA; Pollard AJ
    Vaccine; 2012 Apr; 30(18):2831-8. PubMed ID: 22394992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.
    Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M
    Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigenic determinants driving serogroup-specific antibody response to Neisseria meningitidis C, W, and Y capsular polysaccharides: Insights for rational vaccine design.
    Pietri GP; Bertuzzi S; Karnicar K; Unione L; Lisnic B; Malic S; Miklic K; Novak M; Calloni I; Santini L; Usenik A; Romano MR; Adamo R; Jonjic S; Turk D; Jiménez-Barbero J; Lenac Rovis T
    Carbohydr Polym; 2024 Oct; 341():122349. PubMed ID: 38876728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.
    Fischer M; Carlone GM; Holst J; Williams D; Stephens DS; Perkins BA
    Vaccine; 1999 May; 17(19):2377-83. PubMed ID: 10392619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Active immunization against serogroup B Neisseria meningitidis].
    Navarro-Alonso JA
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):513-9. PubMed ID: 14572386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization.
    Cuello M; Cabrera O; Martinez I; Del Campo JM; Camaraza MA; Sotolongo F; Pérez O; Sierra G
    Vaccine; 2007 Feb; 25(10):1798-805. PubMed ID: 17240485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.